A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
← catalyst calendarSponsored by Exelixis (industry) · EXEL — their whole pipeline →. With Ipsen.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
187actual
Sites
164
Countries
Argentina, Australia, Austria +22
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2018-10-05 | actual | When the study began enrolling |
| Primary completion | 2020-08-19 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-07-31 | estimated | The whole study's end, after follow-up |
| First posted | 2018-10-01 | actual | When this record first appeared on the registry |
| Results posted | 2023-05-18 | actual | When the sponsor posted results to the registry |
| Record updated | 2025-09-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Differentiated Thyroid Cancer
Interventions
- Drug: Cabozantinib — also filed as XL184, Cabometyx®
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFProgression Free Survival (PFS)
measured Up to approximately twenty months after the first subject is randomized. Time from randomization to the earlier of the following events: radiographic PD as determined by the blinded independent central review (BIRC) or death due to any cause.
Objective Response Rate (ORR)
measured Six months after 100 subjects are randomized. Time from randomization to best overall response of confirmed complete response (CR) or confirmed partial response (PR) per BIRC per RECIST 1.1.
Posted documents
hosted by the registry — we link, never re-serveStudy Protocol and Statistical Analysis Planposted 2018-04-30 · 2.5 MB · Prot_SAP_000.pdf
Publications
- PMID 38062732 — linked by the registry
- PMID 34237250 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · EXEL's whole pipeline · Catalyst calendar · Every registered study · What changed